Biomarkers vs real health outcomes

When evaluating new medical interventions, it's common to see results reported in terms of biomarker changes. But it's important to understand the distinction between a biomarker and a clinical outcome, as they are not always interchangeable.

What is a biomarker?

A biomarker is a measurable biological indicator—such as blood pressure, cholesterol level, a molecule in the blood, or a genetic variation—that gives information about some aspect of health or disease. Biomarkers are often used in research to track changes in the body that may be associated with disease risk or treatment effects.

What is a clinical outcome?

A clinical outcome refers to a change in how a person feels, functions, or survives. Examples of clinical outcomes include fewer disease symptoms, improved quality of life, greater ability to perform daily activities, or longer survival.

Why are biomarkers used in research?

Biomarkers are often used in trials because they can be measured more quickly and easily than waiting for clinical outcomes to appear. For example, a study might track a decrease in a certain blood marker rather than waiting years to see if fewer heart attacks occur. In some cases, researchers hope that improving a biomarker will ultimately improve a person’s health.

Limitations of biomarkers

• Not all biomarkers are reliable indicators of real health outcomes. A treatment that changes a biomarker may or may not actually reduce symptoms, prevent disease, or extend life.
• Some biomarkers are only loosely linked to the outcomes patients care about. For example, lowering blood sugar may not always reduce the risk of complications in diabetes if other factors are involved.
• Improvements in a surrogate marker do not automatically mean a person will feel better or live longer. In some cases, focusing too much on a biomarker can lead to interventions that have no benefit—or even cause harm.

Examples

• Cholesterol: Lowering cholesterol is generally associated with reduced heart disease risk, but not all cholesterol-lowering medications have led to fewer heart attacks or deaths in studies.
• Bone density: Drugs that increase bone density may not always decrease the risk of bone fractures, which is the clinical outcome that matters most to patients.
• Tumor size: Cancer treatments that shrink tumors (a biomarker) do not always improve survival or quality of life.

Key point

Changes in biomarkers are only meaningful if they are linked to improvements in outcomes that matter to people—how they feel, function, or survive. It’s important to look beyond biomarkers and examine the real-world benefits and harms of an intervention.

Frequently Asked Questions

• Are biomarkers ever considered proof of benefit?
  Sometimes, but only if the biomarker has been strongly and consistently linked to the clinical outcome through solid evidence.
• Why do researchers rely on biomarkers?
  Because they are easier and quicker to measure than clinical outcomes, especially in short-term studies.
• Can a treatment improve a biomarker and still cause harm?
  Yes. There have been cases where an intervention improved a marker but led to unexpected harms or no improvement in actual health.
• How should I interpret claims about biomarkers?
  Consider whether the change in the biomarker has been proven to result in a meaningful clinical benefit before assuming it is helpful.